Medical Oncologist
CION Cancer Clinics
Y-90 when liver cancer has reached the portal vein: is it safe? | CION Cancer Clinics
Y-90 can be a safe option for some people whose liver cancer has grown into a branch of the portal vein, as long as the liver still works well. It is not safe for everyone. This page explains why the portal vein changes the choice, what the tumour board weighs, who Y-90 does not suit, and how it compares with TACE and treatment given through a drip. At CION Cancer Clinics, a multidisciplinary tumour board weighs your liver function and your scans before recommending any treatment.
NG
Medically reviewed by Dr. Naresh GunduConsultant Medical Oncologist · MBBS, DNB (Internal Medicine), DM (Medical Oncology, AIIMS) · last reviewed October 2026, next review due October 2027
17+specialists on panel
15,000+patients treated
35+centres across Telangana & AP
4.8★ / 800+Google rating
On this page
- Is Y-90 safe if the cancer has grown into the portal vein?
- What decides whether Y-90 is an option for you?
- What happens if Y-90 is being considered?
- How does Y-90 compare with the other options?
- Who is Y-90 not suitable for?
- What this page cannot tell you
- Common questions about Y-90 and portal vein thrombosis
The short answer
Is Y-90 safe if the cancer has grown into the portal vein?
For some people, yes. Y-90 can be a reasonable choice when a primary liver cancer (hepatocellular carcinoma, or HCC) has grown into a branch of the portal vein, the liver's main inflow vessel, and the liver itself is still working well. It is not safe for everyone, and for many people with portal vein involvement the first choice is treatment given through a drip instead.
Why the portal vein changes the question
The liver gets blood from two vessels. The portal vein brings most of it. The hepatic artery brings the rest, and it is the artery that feeds the tumour. When a tumour plug blocks the portal vein, the healthy liver leans more heavily on the artery. A treatment that blocks the artery, such as TACE, can then starve healthy liver as well as tumour. That is why TACE is often avoided here.
Why Y-90 is different
Y-90 (also called TARE or radioembolisation) sends tiny beads carrying radiation into the artery. The beads are very small and mostly do not block the flow. The radiation does the work, not the blockage. That is the main reason specialists consider it when TACE is risky. The technique itself is explained on our Y-90 radioembolisation page.
This page is about cancer that started in the liver. If the cancer in your liver spread from the bowel or elsewhere, the reasoning is different.What the team weighs
What decides whether Y-90 is an option for you?
No single report answers this. The tumour board looks at four things together.
How far the thrombus reaches
A tumour plug in a small branch on one side is very different from one filling the main portal vein. Doctors grade this from Vp1 to Vp4. Branch involvement is where Y-90 is most often discussed. Main trunk involvement carries more risk. Our page on how portal vein involvement is graded explains the scale.
How well the liver works
This matters most of all. Bilirubin (the yellow pigment behind jaundice), albumin (a protein the liver makes) and fluid in the abdomen all count. A liver already struggling may not cope with radiation.
Usually rules it out
- Jaundice
- Fluid in the abdomen that keeps returning
- Confusion from liver failure
Is it tumour or a blood clot?
A plain blood clot in the portal vein is common in cirrhosis and is managed differently. The scans must show which one it is. See tumour thrombus or blood clot.
Spread outside the liver
If the cancer has reached the lungs, bones or lymph nodes, a treatment that works only inside the liver does less. Treatment through the bloodstream usually comes first.
Not sure whether this applies to you?
Ask an oncologistFrom scan to treatment
What happens if Y-90 is being considered?
The scans are reviewed
A recent triple-phase CT or MRI shows the tumour and the vein. CION arranges any missing scans through partner diagnostic centres, and the tumour board reviews them with your blood reports.
The mapping procedure
An interventional radiologist passes a thin tube into the liver artery and maps the blood vessels. A small tracer then shows how much blood leaks to the lungs or gut. This step can rule Y-90 out. Read more on the mapping scan.
The treatment itself
On a separate day, the beads are given through the same kind of tube. CION coordinates Y-90 through accredited partner hospitals, and your team will tell you where it takes place.
Follow-up scans and blood tests
Liver blood tests are repeated in the weeks after. A scan a few months later shows how the tumour and the vein have responded. Your CION oncologist plans this follow-up with you.
Side by side
How does Y-90 compare with the other options?
Option
How it fits when the portal vein is involved
Immunotherapy or targeted tablets
The usual standard first choice, because it treats the whole body. Given at CION centres.
Y-90 radioembolisation
Considered for selected people with branch involvement and good liver function. Through partner hospitals.
TACE
Often avoided, because blocking the artery can harm healthy liver. Sometimes used with care for small branch plugs.
Focused radiation (SBRT)
Can aim at the tumour plug itself, sometimes alongside other treatment. Through partner centres.
Leave a number, we will call you
One field. No form to fill in, and no charge for the call.
Being honest about fit
Who is Y-90 not suitable for?
Y-90 does not suit someone whose liver is already failing. If there is jaundice, hard-to-control fluid in the abdomen or episodes of confusion, the radiation can push a weak liver into failure. Comfort-focused care and careful support of the liver are usually kinder.
When the main vein is fully blocked
A tumour plug filling the main trunk of the portal vein raises the risk of liver damage. Some specialist teams still treat selected cases, but many will recommend atezolizumab plus bevacizumab or another systemic option first.
When the mapping scan shows too much leakage
If too much tracer reaches the lungs, the beads could harm them. If vessels feeding the stomach or bowel cannot be safely closed off, the beads could cause ulcers. Either finding can stop the plan.
When the evidence does not favour it
Large trials comparing Y-90 with tablets in advanced liver cancer did not show that Y-90 helps people live longer overall. Some people tolerated it better. That is why Y-90 here is a selected choice, decided case by case, and not the default.
Being straight with you
What this page cannot tell you
It cannot tell you whether Y-90 is safe for your liver. That depends on your exact scans, your blood results and the mapping procedure, read together by a liver tumour board. Two people with the same words on a report can be given different advice for good reasons.
It cannot predict how you will respond
Nobody can promise that the tumour plug will shrink or that the vein will reopen. Response is checked on later scans, not assumed. Be wary of anyone who tells you otherwise before treatment.
Who to ask
Bring your CT or MRI films, the written reports and your latest liver blood tests to a CION medical oncologist. The case can be taken to the tumour board, which includes interventional radiology input through partner hospitals. If you already have a plan from elsewhere, a second opinion is a normal request.
If you notice yellow eyes, a swelling belly or new confusion after any liver treatment, contact your team the same day.Questions we are asked
Common questions about Y-90 and portal vein thrombosis
Can Y-90 be done if there is a clot in the portal vein?
Sometimes. If the clot is tumour in a branch of the vein and the liver works well, Y-90 is one option the tumour board may weigh. If it is fully blocking the main vein, or the liver is weak, the answer is usually no. The scans and blood tests decide, not the word clot on its own.
Why was I told TACE is not safe but Y-90 might be?
TACE works partly by blocking the liver artery. When the portal vein is already blocked, healthy liver depends on that artery, so blocking it can cause liver failure. Y-90 beads are much smaller and mostly leave the artery open, which is why it is sometimes considered when TACE is not.
Is Y-90 better than immunotherapy for this?
Not as a rule. Treatment through the bloodstream is usually the standard first choice when the portal vein is involved, because it also reaches cancer outside the liver. Y-90 may be chosen for selected people, or combined with other treatment. Your oncologist will explain why one is preferred for you.
Will Y-90 clear the tumour from the vein?
It may shrink it in some people, and in others it does not. Nobody can say in advance. Response is judged on a scan some months after treatment, alongside liver blood tests. The aim is control of the cancer while protecting the liver you still have.
Does CION do Y-90 itself?
No. CION's oncologists assess you, the tumour board discusses your case, and CION coordinates the mapping procedure and the Y-90 treatment through accredited partner hospitals. Your team will tell you where each step takes place and stays with you for follow-up.
Do I need blood thinners for a tumour thrombus?
Not usually for the tumour plug itself. A plain blood clot is a separate question, and bleeding risk in cirrhosis must be weighed. Never start or stop a blood thinner without your doctor. Our page on blood thinners and tumour thrombus explains more.
Is Y-90 covered by Aarogyasri or insurance?
Cover depends on the scheme, the policy and the hospital, and the rules change. Y-90 is among the costlier liver treatments, so ask the treating hospital for a written, itemised estimate and check cover before the date is fixed. CION's team can help with scheme paperwork.
What should I bring to the first appointment?
Bring the CT or MRI films and reports, any biopsy report, recent liver blood tests and a list of every medicine you take, including herbal ones. If a family member reads English more easily, bring them too. One helpline serves every CION centre.
Your Specialists
Meet CION's liver cancer specialists. Bring your scan reports and liver blood tests.
Our medical and surgical oncologists plan liver cancer care together, weighing the tumour and how well your liver works before choosing surgery, a liver-directed procedure or medicines.
Medical Oncologist
Dr. C. Raghavendra Reddy
MBBS(Gold Medal), DNB(General Medicine), DM(Medical Oncology)(Gold Medal)
Medical Oncologist
Dr. Bharati Devi Gorantla
MBBS, MD(General Medicine), DM(Medical Oncology)(Adyar,Chennai), ECMO, MRCP SCE(UK)
Medical Oncologist
Dr. Owais Mohammed
MBBS, MD (General Medicine), DrNB (Medical Oncology), ECMO, MRCP SCE (Medical Oncology) (UK)
Medical Oncologist
Medical Oncologist
Surgical Oncologist
Dr. Muralidhar Muddusetty
MBBS (AIIMS), MS (Surgery) (AIIMS), DNB (Surgical Oncology), MRCS (Edinburgh)
Surgical Oncologist
Want a specific doctor for your case? Mention them when booking.
Book Free ConsultationBook an appointment with our specialist
Share your name and number — we'll call you back within 30 minutes to schedule your consultation.
Sources
- RadiologyInfo.org (RSNA/ACR) — Radioembolization (Y90)
- Merck Manual Consumer Version — Portal Vein Thrombosis
- American Cancer Society — Embolization Therapy for Liver Cancer
- EASL — EASL Clinical Practice Guidelines: management of hepatocellular carcinoma
This page is general information, not a prescription. Do not change or stop any treatment based on what you read here. If anything is worrying you, contact your own treating team — or call our helpline and we will help you reach the right specialist.
Keep reading
Related pages
Portal Vein Tumour Thrombosis ExplainedWhat a tumour plug in the portal vein actually isTreatment Options With Portal Vein InvolvementEvery option on the table, not only Y-90Who Is Suitable for Y-90?The general checks before any Y-90 treatmentTACE vs TARE: How the Choice Is MadeWhy one is chosen over the other
Talk to us
Were you told the portal vein is involved?
Send us your scan reports and liver blood tests, and a CION oncologist can take your case to the tumour board to weigh Y-90 against the other options. One helpline serves every CION centre.